July 01, 2025 09:00 ET | Source: Inmagene Biopharmaceuticals The ADAPTIVE Phase 2b trial evaluates multiple dose regimens of IMG-007…
New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for…
Phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic pancreatic cancer (mPDAC) treated with elraglusib June 20,…
Larry Cermak transitions to President role to focus on research and product innovation; Kaleb Jessee promoted to CEO NEW YORK,…
June 16, 2025 19:20 ET | Source: PolyPid Ltd. The Company Anticipates that with this Additional Funding, PolyPid’s Runway would…
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage…
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever…
TAINAN, June 13, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the launch of its global Phase II clinical trial…
June 06, 2025 16:05 ET | Source: PolyPid Ltd. PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD),…
June 06, 2025 16:07 ET | Source: Restem MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology…